| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus | 37 | 2023 | 806 | 7.510 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 19 | 2024 | 119 | 5.210 |
Why?
|
| Sulfonylurea Compounds | 14 | 2024 | 64 | 3.250 |
Why?
|
| Diabetes Mellitus, Type 1 | 19 | 2024 | 567 | 3.050 |
Why?
|
| Genetic Testing | 10 | 2021 | 535 | 2.780 |
Why?
|
| Insulin | 15 | 2023 | 1160 | 2.280 |
Why?
|
| Mutation | 29 | 2024 | 3968 | 1.960 |
Why?
|
| Infant, Newborn | 30 | 2024 | 2380 | 1.770 |
Why?
|
| Hypoglycemic Agents | 11 | 2020 | 378 | 1.710 |
Why?
|
| Infant, Newborn, Diseases | 7 | 2021 | 111 | 1.660 |
Why?
|
| Precision Medicine | 6 | 2023 | 395 | 1.600 |
Why?
|
| Pancreas | 6 | 2024 | 239 | 1.140 |
Why?
|
| Registries | 7 | 2019 | 702 | 1.100 |
Why?
|
| Infant | 18 | 2022 | 3047 | 1.060 |
Why?
|
| Hyperglycemia | 5 | 2019 | 176 | 1.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2022 | 1373 | 0.900 |
Why?
|
| Insulin-Secreting Cells | 5 | 2020 | 397 | 0.790 |
Why?
|
| Internet | 2 | 2015 | 312 | 0.780 |
Why?
|
| Forkhead Transcription Factors | 3 | 2017 | 166 | 0.770 |
Why?
|
| Humans | 70 | 2024 | 86644 | 0.750 |
Why?
|
| Glyburide | 5 | 2024 | 32 | 0.750 |
Why?
|
| Genetic Diseases, X-Linked | 2 | 2017 | 34 | 0.730 |
Why?
|
| Immune System Diseases | 2 | 2017 | 26 | 0.720 |
Why?
|
| Developmental Disabilities | 4 | 2016 | 195 | 0.710 |
Why?
|
| Hypoglycemia | 2 | 2017 | 107 | 0.690 |
Why?
|
| GATA6 Transcription Factor | 2 | 2020 | 13 | 0.690 |
Why?
|
| Diarrhea | 2 | 2017 | 182 | 0.680 |
Why?
|
| Hyperinsulinism | 2 | 2019 | 51 | 0.650 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 2 | 2018 | 80 | 0.650 |
Why?
|
| Lamin Type A | 1 | 2018 | 24 | 0.630 |
Why?
|
| Sulfonylurea Receptors | 7 | 2024 | 50 | 0.630 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2021 | 456 | 0.620 |
Why?
|
| Ovotesticular Disorders of Sex Development | 1 | 2017 | 4 | 0.600 |
Why?
|
| Insulin Resistance | 2 | 2019 | 377 | 0.600 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2017 | 10 | 0.600 |
Why?
|
| Congenital Hyperinsulinism | 3 | 2024 | 13 | 0.590 |
Why?
|
| Child, Preschool | 12 | 2018 | 3612 | 0.580 |
Why?
|
| Glucokinase | 4 | 2019 | 61 | 0.560 |
Why?
|
| Abnormalities, Multiple | 2 | 2018 | 232 | 0.560 |
Why?
|
| Receptor, Insulin | 1 | 2016 | 54 | 0.550 |
Why?
|
| Estradiol | 1 | 2017 | 252 | 0.550 |
Why?
|
| Male | 38 | 2023 | 40966 | 0.540 |
Why?
|
| Child | 16 | 2022 | 6927 | 0.540 |
Why?
|
| Homozygote | 1 | 2016 | 200 | 0.540 |
Why?
|
| Insulin, Regular, Human | 1 | 2015 | 7 | 0.540 |
Why?
|
| Self-Help Groups | 1 | 2015 | 14 | 0.530 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2016 | 114 | 0.530 |
Why?
|
| Testosterone | 1 | 2017 | 271 | 0.530 |
Why?
|
| Gene Deletion | 1 | 2016 | 329 | 0.530 |
Why?
|
| Adolescent | 17 | 2022 | 8981 | 0.520 |
Why?
|
| Exons | 1 | 2016 | 450 | 0.510 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2012 | 101 | 0.500 |
Why?
|
| Female | 39 | 2024 | 44533 | 0.500 |
Why?
|
| Introns | 1 | 2015 | 289 | 0.490 |
Why?
|
| Antigens, CD | 1 | 2016 | 458 | 0.480 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 51 | 0.470 |
Why?
|
| Family | 1 | 2015 | 311 | 0.460 |
Why?
|
| Microcephaly | 1 | 2013 | 75 | 0.460 |
Why?
|
| Infant, Premature, Diseases | 1 | 2014 | 78 | 0.460 |
Why?
|
| Epilepsy, Generalized | 1 | 2013 | 37 | 0.460 |
Why?
|
| Receptors, Drug | 3 | 2011 | 54 | 0.450 |
Why?
|
| Point Mutation | 1 | 2013 | 246 | 0.440 |
Why?
|
| Neonatal Screening | 2 | 2018 | 59 | 0.440 |
Why?
|
| ATP-Binding Cassette Transporters | 3 | 2011 | 141 | 0.430 |
Why?
|
| Blood Glucose | 4 | 2020 | 873 | 0.420 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2020 | 2271 | 0.410 |
Why?
|
| DNA-Binding Proteins | 2 | 2018 | 1208 | 0.400 |
Why?
|
| Genetic Variation | 1 | 2018 | 1351 | 0.380 |
Why?
|
| Insulin Infusion Systems | 2 | 2021 | 36 | 0.380 |
Why?
|
| Pancreas, Artificial | 2 | 2021 | 28 | 0.370 |
Why?
|
| Genomics | 2 | 2013 | 720 | 0.370 |
Why?
|
| Carrier Proteins | 1 | 2013 | 673 | 0.360 |
Why?
|
| Fatal Outcome | 3 | 2016 | 293 | 0.360 |
Why?
|
| Transcription Factors | 2 | 2018 | 1565 | 0.360 |
Why?
|
| B-Lymphocytes | 6 | 2005 | 724 | 0.330 |
Why?
|
| Adult | 20 | 2024 | 25648 | 0.330 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1196 | 0.290 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2003 | 425 | 0.290 |
Why?
|
| Islets of Langerhans | 4 | 2005 | 544 | 0.280 |
Why?
|
| Consensus | 3 | 2023 | 335 | 0.280 |
Why?
|
| Autoantibodies | 4 | 2024 | 267 | 0.280 |
Why?
|
| Amino Acid Substitution | 3 | 2016 | 339 | 0.270 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2016 | 28 | 0.270 |
Why?
|
| Neurologic Manifestations | 2 | 2016 | 11 | 0.260 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 39 | 0.230 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 1565 | 0.230 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 696 | 0.230 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2002 | 76 | 0.220 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2021 | 104 | 0.210 |
Why?
|
| Growth and Development | 1 | 2022 | 12 | 0.210 |
Why?
|
| T-Lymphocytes | 4 | 2018 | 1195 | 0.210 |
Why?
|
| Case-Control Studies | 2 | 2017 | 1805 | 0.210 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 853 | 0.200 |
Why?
|
| Organoids | 1 | 2021 | 61 | 0.200 |
Why?
|
| Self-Management | 1 | 2021 | 29 | 0.200 |
Why?
|
| Mutation, Missense | 2 | 2016 | 276 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2012 | 125 | 0.190 |
Why?
|
| Endocrinology | 2 | 2020 | 66 | 0.190 |
Why?
|
| United States | 8 | 2021 | 6672 | 0.190 |
Why?
|
| Age of Onset | 2 | 2018 | 310 | 0.190 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 171 | 0.180 |
Why?
|
| Heterozygote | 3 | 2023 | 365 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 454 | 0.180 |
Why?
|
| Psychomotor Performance | 2 | 2013 | 492 | 0.180 |
Why?
|
| Prognosis | 2 | 2018 | 3679 | 0.180 |
Why?
|
| Lymphocyte Activation | 6 | 2003 | 728 | 0.170 |
Why?
|
| Siblings | 2 | 2016 | 111 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 302 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1801 | 0.170 |
Why?
|
| Down Syndrome | 1 | 2019 | 53 | 0.170 |
Why?
|
| Pregnancy in Diabetics | 1 | 2018 | 37 | 0.170 |
Why?
|
| Genomic Imprinting | 1 | 2018 | 33 | 0.160 |
Why?
|
| Histone Demethylases | 1 | 2018 | 30 | 0.160 |
Why?
|
| Vestibular Diseases | 1 | 2018 | 27 | 0.160 |
Why?
|
| Cellular Reprogramming | 1 | 2018 | 37 | 0.160 |
Why?
|
| Patient Participation | 1 | 2020 | 216 | 0.160 |
Why?
|
| Gene Editing | 1 | 2018 | 42 | 0.160 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 79 | 0.160 |
Why?
|
| Infant, Extremely Premature | 1 | 2017 | 24 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2001 | 533 | 0.160 |
Why?
|
| Europe | 1 | 2018 | 309 | 0.150 |
Why?
|
| Face | 1 | 2018 | 114 | 0.150 |
Why?
|
| Genetic Markers | 1 | 2018 | 476 | 0.150 |
Why?
|
| Chromosomes, Human, Y | 1 | 2017 | 22 | 0.150 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 160 | 0.150 |
Why?
|
| Prevalence | 2 | 2018 | 1239 | 0.150 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 247 | 0.150 |
Why?
|
| Epilepsy | 2 | 2012 | 397 | 0.150 |
Why?
|
| Mosaicism | 1 | 2017 | 67 | 0.150 |
Why?
|
| Young Adult | 7 | 2020 | 5976 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 2 | 2016 | 286 | 0.150 |
Why?
|
| Autopsy | 1 | 2017 | 116 | 0.140 |
Why?
|
| Testis | 1 | 2017 | 152 | 0.140 |
Why?
|
| Acanthosis Nigricans | 1 | 2016 | 3 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2018 | 2767 | 0.140 |
Why?
|
| Mice, Inbred NOD | 5 | 2005 | 187 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2018 | 8489 | 0.140 |
Why?
|
| Drug Resistance | 1 | 2017 | 256 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 3362 | 0.140 |
Why?
|
| Pedigree | 3 | 2023 | 966 | 0.140 |
Why?
|
| Goals | 2 | 2007 | 67 | 0.130 |
Why?
|
| Gestational Age | 1 | 2016 | 311 | 0.130 |
Why?
|
| Ovary | 1 | 2017 | 258 | 0.130 |
Why?
|
| Infant, Premature | 1 | 2017 | 290 | 0.130 |
Why?
|
| Recombinant Proteins | 2 | 2016 | 1014 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 77 | 0.130 |
Why?
|
| Endocrine System Diseases | 1 | 2015 | 23 | 0.130 |
Why?
|
| Models, Theoretical | 2 | 2019 | 482 | 0.130 |
Why?
|
| Turner Syndrome | 1 | 2015 | 27 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 115 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 45 | 0.130 |
Why?
|
| Community Networks | 1 | 2015 | 29 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 532 | 0.130 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 183 | 0.130 |
Why?
|
| Biomarkers | 2 | 2020 | 1718 | 0.120 |
Why?
|
| Diazoxide | 1 | 2014 | 19 | 0.120 |
Why?
|
| Pediatrics | 1 | 2018 | 344 | 0.120 |
Why?
|
| Intensive Care, Neonatal | 1 | 2014 | 13 | 0.120 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 502 | 0.120 |
Why?
|
| Blindness, Cortical | 1 | 2013 | 8 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2018 | 536 | 0.120 |
Why?
|
| Intestinal Atresia | 1 | 2013 | 4 | 0.120 |
Why?
|
| Duodenal Obstruction | 1 | 2013 | 4 | 0.120 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2013 | 11 | 0.120 |
Why?
|
| Gallbladder | 1 | 2013 | 30 | 0.120 |
Why?
|
| Digestive System Abnormalities | 1 | 2013 | 13 | 0.120 |
Why?
|
| Intestinal Volvulus | 1 | 2013 | 10 | 0.120 |
Why?
|
| Chicago | 3 | 2016 | 1379 | 0.120 |
Why?
|
| Genome, Human | 1 | 2018 | 756 | 0.110 |
Why?
|
| Pancreatic Diseases | 1 | 2013 | 52 | 0.110 |
Why?
|
| Congenital Abnormalities | 1 | 2013 | 63 | 0.110 |
Why?
|
| Career Choice | 2 | 2005 | 139 | 0.110 |
Why?
|
| Uniparental Disomy | 1 | 2012 | 5 | 0.110 |
Why?
|
| Syndrome | 2 | 2013 | 446 | 0.110 |
Why?
|
| Psychomotor Disorders | 1 | 2012 | 20 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2020 | 7993 | 0.110 |
Why?
|
| Premature Birth | 1 | 2014 | 113 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 151 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 526 | 0.110 |
Why?
|
| Epidemiologic Research Design | 1 | 2011 | 22 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 3640 | 0.100 |
Why?
|
| Pregnancy | 4 | 2024 | 2894 | 0.100 |
Why?
|
| Mice | 13 | 2018 | 11352 | 0.100 |
Why?
|
| Brain | 1 | 2021 | 2216 | 0.100 |
Why?
|
| Time Factors | 2 | 2019 | 5210 | 0.100 |
Why?
|
| Animals | 16 | 2018 | 26582 | 0.100 |
Why?
|
| HLA-DQ Antigens | 1 | 2011 | 52 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2015 | 428 | 0.100 |
Why?
|
| Autoimmunity | 2 | 2018 | 160 | 0.100 |
Why?
|
| Longitudinal Studies | 2 | 2011 | 1019 | 0.100 |
Why?
|
| Autoimmune Diseases | 2 | 2003 | 241 | 0.100 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2021 | 57 | 0.090 |
Why?
|
| KATP Channels | 1 | 2010 | 19 | 0.090 |
Why?
|
| Quality of Life | 1 | 2018 | 1585 | 0.090 |
Why?
|
| Middle Aged | 6 | 2024 | 25028 | 0.090 |
Why?
|
| eIF-2 Kinase | 1 | 2010 | 46 | 0.090 |
Why?
|
| Tooth Discoloration | 1 | 2009 | 2 | 0.090 |
Why?
|
| Students, Medical | 2 | 2005 | 384 | 0.090 |
Why?
|
| Lymphocyte Transfusion | 2 | 1999 | 41 | 0.090 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 1999 | 39 | 0.090 |
Why?
|
| Isoantigens | 5 | 1999 | 66 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2010 | 342 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2012 | 628 | 0.080 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 636 | 0.080 |
Why?
|
| Education, Graduate | 1 | 2007 | 11 | 0.080 |
Why?
|
| Algorithms | 2 | 2015 | 1830 | 0.070 |
Why?
|
| Lymphocytes | 2 | 1999 | 464 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2008 | 207 | 0.070 |
Why?
|
| Incidence | 1 | 2011 | 1577 | 0.070 |
Why?
|
| Attitude | 1 | 2007 | 127 | 0.070 |
Why?
|
| Research | 2 | 2005 | 253 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2018 | 372 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2005 | 158 | 0.070 |
Why?
|
| Consumer Behavior | 1 | 2005 | 29 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2002 | 252 | 0.060 |
Why?
|
| Education, Medical | 1 | 2007 | 233 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2024 | 4214 | 0.060 |
Why?
|
| Mice, Mutant Strains | 2 | 2001 | 229 | 0.060 |
Why?
|
| Chemokines, CC | 1 | 2003 | 34 | 0.060 |
Why?
|
| Mice, Transgenic | 3 | 2003 | 1540 | 0.060 |
Why?
|
| Phenotype | 3 | 2016 | 2378 | 0.060 |
Why?
|
| Myocarditis | 1 | 2003 | 50 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 8 | 2005 | 3092 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2007 | 376 | 0.060 |
Why?
|
| Adenosine Triphosphate | 1 | 2024 | 314 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2003 | 164 | 0.060 |
Why?
|
| Orthopedics | 1 | 2004 | 124 | 0.050 |
Why?
|
| Organ Size | 1 | 2023 | 364 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2002 | 148 | 0.050 |
Why?
|
| Birth Weight | 2 | 2018 | 145 | 0.050 |
Why?
|
| Agammaglobulinemia | 1 | 2002 | 20 | 0.050 |
Why?
|
| Antigen Presentation | 2 | 2003 | 209 | 0.050 |
Why?
|
| Cell Communication | 1 | 2003 | 194 | 0.050 |
Why?
|
| Mice, Inbred C3H | 5 | 1999 | 370 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2002 | 148 | 0.050 |
Why?
|
| Glutamate Decarboxylase | 2 | 2011 | 32 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 429 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2001 | 299 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2021 | 401 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 143 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2021 | 268 | 0.050 |
Why?
|
| Expert Testimony | 1 | 2020 | 46 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 188 | 0.050 |
Why?
|
| Computer Literacy | 1 | 2020 | 2 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 127 | 0.050 |
Why?
|
| Attitude to Computers | 1 | 2020 | 12 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 196 | 0.050 |
Why?
|
| Patch-Clamp Techniques | 1 | 2021 | 396 | 0.050 |
Why?
|
| Spleen | 1 | 2001 | 430 | 0.050 |
Why?
|
| Monitoring, Ambulatory | 1 | 2020 | 32 | 0.050 |
Why?
|
| Gain of Function Mutation | 1 | 2020 | 13 | 0.050 |
Why?
|
| Nitrogen | 1 | 1980 | 70 | 0.050 |
Why?
|
| Fetal Growth Retardation | 1 | 1980 | 66 | 0.050 |
Why?
|
| Organogenesis | 1 | 2020 | 41 | 0.050 |
Why?
|
| Zinc | 1 | 1980 | 91 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2020 | 71 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2020 | 116 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2021 | 989 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 5 | 1999 | 1047 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2018 | 2818 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2020 | 42 | 0.040 |
Why?
|
| Neural Pathways | 1 | 2021 | 308 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 278 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1999 | 66 | 0.040 |
Why?
|
| Histocompatibility Antigens | 1 | 1999 | 35 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2021 | 429 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2021 | 294 | 0.040 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2018 | 7 | 0.040 |
Why?
|
| CD28 Antigens | 1 | 1999 | 88 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2021 | 729 | 0.040 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 36 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 203 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 69 | 0.040 |
Why?
|
| Abortion, Spontaneous | 1 | 2018 | 66 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 34 | 0.040 |
Why?
|
| International Cooperation | 1 | 2018 | 127 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 294 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 70 | 0.040 |
Why?
|
| Nerve Net | 1 | 2021 | 366 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 391 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2018 | 140 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1999 | 292 | 0.040 |
Why?
|
| Intellectual Disability | 1 | 2018 | 186 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 455 | 0.040 |
Why?
|
| Legal Guardians | 1 | 2016 | 7 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 1999 | 337 | 0.040 |
Why?
|
| Selection Bias | 1 | 2016 | 37 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2016 | 194 | 0.030 |
Why?
|
| Cell Division | 3 | 2005 | 696 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 508 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1673 | 0.030 |
Why?
|
| Succinimides | 3 | 1999 | 13 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1204 | 0.030 |
Why?
|
| Fluoresceins | 3 | 1999 | 43 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 3 | 1999 | 74 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 45 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2015 | 59 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2705 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 288 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 674 | 0.030 |
Why?
|
| Consanguinity | 1 | 2014 | 73 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 572 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 685 | 0.030 |
Why?
|
| Aged | 1 | 2011 | 18415 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2020 | 1458 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2013 | 30 | 0.030 |
Why?
|
| Parents | 1 | 2016 | 272 | 0.030 |
Why?
|
| Fluorescent Dyes | 3 | 1999 | 242 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1621 | 0.030 |
Why?
|
| Risk Factors | 1 | 2024 | 5417 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 582 | 0.030 |
Why?
|
| Chromosome Duplication | 1 | 2012 | 8 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2012 | 53 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 138 | 0.030 |
Why?
|
| Eye Movements | 1 | 2013 | 119 | 0.030 |
Why?
|
| Hand | 1 | 2013 | 130 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 2 | 2005 | 139 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2012 | 229 | 0.030 |
Why?
|
| Fathers | 1 | 2012 | 70 | 0.030 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2011 | 16 | 0.030 |
Why?
|
| Research Design | 1 | 2015 | 594 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1961 | 0.020 |
Why?
|
| C-Peptide | 1 | 2011 | 174 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1851 | 0.020 |
Why?
|
| Dental Enamel Hypoplasia | 1 | 2009 | 2 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 1999 | 89 | 0.020 |
Why?
|
| Haplotypes | 1 | 2011 | 642 | 0.020 |
Why?
|
| Adoptive Transfer | 2 | 1999 | 168 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2007 | 2501 | 0.020 |
Why?
|
| Proinsulin | 1 | 2007 | 124 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2007 | 143 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2007 | 623 | 0.020 |
Why?
|
| Chimera | 1 | 2005 | 56 | 0.020 |
Why?
|
| Protein Folding | 1 | 2007 | 282 | 0.020 |
Why?
|
| Potassium Channels | 1 | 2007 | 340 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2005 | 75 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 307 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 141 | 0.020 |
Why?
|
| Job Satisfaction | 1 | 2005 | 73 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 963 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 364 | 0.010 |
Why?
|
| Chemotaxis | 1 | 2003 | 72 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 2062 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2003 | 127 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2003 | 146 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 3030 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2003 | 444 | 0.010 |
Why?
|
| Education, Medical, Graduate | 1 | 2005 | 369 | 0.010 |
Why?
|
| Myocardium | 1 | 2003 | 529 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 1749 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2003 | 559 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 1999 | 23 | 0.010 |
Why?
|
| Lymphopenia | 1 | 1999 | 28 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 1999 | 39 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1999 | 171 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1999 | 47 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1999 | 211 | 0.010 |
Why?
|
| Transplantation Immunology | 1 | 1999 | 84 | 0.010 |
Why?
|
| Feces | 1 | 1980 | 319 | 0.010 |
Why?
|
| Diet | 1 | 1980 | 443 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1999 | 679 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1999 | 996 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 1999 | 409 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 1920 | 0.010 |
Why?
|
| Rats | 1 | 1980 | 3990 | 0.010 |
Why?
|